Health Care & Life Sciences » Biotechnology | Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals Inc. | Cash Flow

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
424
348
636
896
1,199
2,444
Depreciation, Depletion & Amortization
41
53
75
105
145
148
Other Funds
22
114
329
787
302
440
Funds from Operations
774
723
1,101
1,245
2,234
2,892
Changes in Working Capital
191
20
230
228
927
697
Net Operating Cash Flow
584
743
1,331
1,473
1,307
2,195
Capital Expenditures
156
333
678
512
273
Purchase/Sale of Investments
199
88
230
535
733
Net Investing Cash Flow
355
421
908
1,047
1,005
Issuance/Reduction of Debt, Net
2
222
140
41
37
Net Financing Cash Flow
77
209
263
700
24
Net Change in Cash
305
113
160
274
278
Free Cash Flow
427
410
653
961
1,034
Deferred Taxes & Investment Tax Credit
64
67
122
360
319
140
Change in Capital Stock
57
126
206
127
240

About Regeneron Pharmaceuticals

View Profile
Address
777 Old Saw Mill River Road
Tarrytown New York 10591
United States
Employees -
Website http://www.regeneron.com
Updated 07/08/2019
Regeneron Pharmaceuticals, Inc. engages in the discovery, invention, development, manufacture, and commercialization of medicines for the treatment of serious diseases. It products include the following brands: EYLEA, Dupixent, Praluent, Kevzara, ARCALYST, and ZALTRAP. The company was founded by Alferd G.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.